Eric Strangeland

Title: Eric Strangeland: Innovator in Pharmaceutical Compounds

Introduction

Eric Strangeland is a notable inventor based in Pacifica, California. He has made significant contributions to the field of pharmaceuticals, particularly in the development of serotonin and norepinephrine reuptake inhibitors. His work has implications for various therapeutic applications.

Latest Patents

Eric Strangeland holds a patent for 3-phenoxymethylpyrrolidine compounds. This invention relates to compounds of formula I, which are defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds are designed to act as serotonin and norepinephrine reuptake inhibitors. Additionally, the patent covers pharmaceutical compositions comprising such compounds, methods of using them, and processes for preparing these compounds.

Career Highlights

Throughout his career, Eric has worked with prominent companies in the pharmaceutical industry, including Theravance, Inc. and Theravance Respiratory Company, LLC. His experience in these organizations has allowed him to contribute to innovative drug development and research.

Collaborations

Eric has collaborated with talented individuals in his field, including Daisuke Roland Saito and Adam D. Hughes. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Eric Strangeland's work in developing pharmaceutical compounds showcases his dedication to advancing medical science. His patent for 3-phenoxymethylpyrrolidine compounds highlights his innovative contributions to the field.